

# Antongiulio Faggiano

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6857062/antongiulio-faggiano-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272 papers	7,532 citations	44 h-index	76 g-index
305 ext. papers	8,911 ext. citations	4.9 avg, IF	5.66 L-index

#	Paper	IF	Citations
272	Angiogenic factors as prognostic markers in neuroendocrine neoplasms.. <i>Endocrine</i> , <b>2022</b> , 1	4	1
271	Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 45, 849	5.2	3
270	Understanding care relationships in diabetes practice: A psychodynamic interview-based exploratory study.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263226	3.7	0
269	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e220290	10.4	0
268	Prognostic significance of laterality in lung neuroendocrine tumors.. <i>Endocrine</i> , <b>2022</b> , 1	4	0
267	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.. <i>Journal of Neuroendocrinology</i> , <b>2022</b> , e13105	3.8	4
266	Sex differences in carcinoid syndrome: A gap to be closed.. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2022</b> , 1	10.5	0
265	A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep.. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2022</b> , 1-18	11.5	0
264	Erectile dysfunction as a marker of endocrine and glycemic disorders.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	0
263	The Strange Case of a Pancreatic Neuroendocrine Carcinoma With Low Proliferation Index and Atypical Clinical Behavior.. <i>Pancreas</i> , <b>2022</b> , 51, e25-e27	2.6	
262	Pancreatic Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 696-704	5.6	4
261	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.. <i>Critical Reviews in</i>	7	1
260	Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. <i>Translational Oncology</i> , <b>2021</b> , 15, 101269	4.9	0
259	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
258	Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 680305	5.7	0
257	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 563-579	10.5	6
256	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 511-525	10.5	2

255	Foreword to the special issue on advances in neuroendocrine neoplasms. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 493-494	10.5	
254	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 649496	5.7	7
253	Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
252	Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 665631	5.7	3
251	Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 667784	5.7	4
250	Multiparametric ultrasound evaluation of a case of bilateral carotid body tumor. <i>Journal of Ultrasound</i> , <b>2021</b> , 24, 311-315	3.4	2
249	Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 665698	5.7	0
248	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ�Italiana Endocrinologia (SIE)/Societ�Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> ,	6	3
247	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ�Italiana Endocrinologia (SIE)/Societ�Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , <b>2021</b> , 6, 100155	6	3
246	Sunitinib Treatment for Advanced Paraganglioma: Case Report of a Novel SDHD Gene Mutation Variant and Systematic Review of the Literature. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 677983	5.3	1
245	Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 700806	5.7	0
244	Vantaggi e limiti degli attuali kit di dosaggio della Vitamina D. <i>L Endocrinologo</i> , <b>2021</b> , 22, 42-44	0	
243	Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 651438	5.7	0
242	Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 672499	5.7	1
241	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 367-374	3.3	3
240	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 989-994	5.2	6
239	Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e316-e327	5.6	3
238	Neuroendocrine Neoplasms with Peculiar Biology and Features: MEN1, MEN2A, MEN2B, MEN4, VHL, NF1 <b>2021</b> , 233-267		

237	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 324	8.5	3
236	NETest: a systematic review focusing on the prognostic and predictive role. <i>Neuroendocrinology</i> , <b>2021</b> ,	5.6	2
235	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2021</b> , e3494	7.5	6
234	L'approccio con analoghi della somatostatina nelle neoplasie neuroendocrine associate a sindromi neoplastiche multi-endocrine ereditarie. <i>L'Endocrinologo</i> , <b>2021</b> , 22, 423	0	
233	Letter to the editor: how the COVID-19 pandemic has changed outpatient diagnosis in the andrological setting. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 1	5.2	2
232	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. <i>Endocrine</i> , <b>2021</b> , 1	4	2
231	ENETS consensus guidelines for synoptic reporting of radiology studies. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , e13044	3.8	6
230	MEN2 in Clinical Practice. <i>Endocrinology</i> , <b>2021</b> , 1-8	0.1	
229	1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results. <i>Annals of Oncology</i> , <b>2020</b> , 31, S773	10.3	4
228	Ruolo diagnostico, prognostico e predittivo di risposta del NETest nelle neoplasie neuroendocrine. <i>L'Endocrinologo</i> , <b>2020</b> , 21, 432-440	0	
227	Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
226	A Novel MAX Gene Mutation Variant in a Patient With Multiple and "Composite" Neuroendocrine-Neuroblastic Tumors. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 234	5.7	9
225	Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature. <i>Endocrine</i> , <b>2020</b> , 69, 73-78	4	1
224	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , <b>2020</b> , 69, 441-450	10	
223	Gli effetti del lanreotide sulla captazione del 68Ga-DOTATATE nei pazienti con tumore neuroendocrino: una valutazione intra-paziente prospettica. <i>L'Endocrinologo</i> , <b>2020</b> , 21, 66-67	0	
222	Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2020</b> , 21, 599-612	10.5	14
221	An incidental rectal neuroendocrine microcarcinoma ('micro-NEC') coexistent with a high grade adenoma. <i>Pathology International</i> , <b>2020</b> , 70, 300-302	1.8	0
220	Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?. <i>Trends in Endocrinology and Metabolism</i> , <b>2020</b> , 31, 631-641	8.8	6

219	Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1047	5.3	5
218	Predictors of malignancy in high-risk indeterminate (TIR3B) cytopathology thyroid nodules. <i>Journal of Endocrinological Investigation</i> , <b>2020</b> , 43, 1115-1123	5.2	4
217	Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
216	L'indicazione chirurgica delle neoplasie neuroendocrine del pancreas associate a MEN 1 si basa su dimensioni del tumore e curva di crescita. <i>L'Endocrinologo</i> , <b>2020</b> , 21, 51-52	0	
215	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , <b>2020</b> , 25, 259-265	5.7	9
214	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	5
213	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2020</b> , 182, 439-446	6.5	11
212	ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. <i>European Journal of Endocrinology</i> , <b>2020</b> , 183, R197-R215	6.5	8
211	SUN-136 Clinico-Pathological Features, Treatment Modalities and Survival of Patients with Malignant Insulinoma: A Multicenter Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
210	Bone metabolism, bone mass and structural integrity profile in professional male football players. <i>Journal of Sports Medicine and Physical Fitness</i> , <b>2020</b> , 60, 912-918	1.4	2
209	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 10,	5.1	10
208	Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma. <i>Endocrine</i> , <b>2020</b> , 67, 597-604	4	2
207	Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 146, 102840	7	4
206	Vitamin D testing: advantages and limits of the current assays. <i>European Journal of Clinical Nutrition</i> , <b>2020</b> , 74, 231-247	5.2	37
205	Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPAR $\gamma$ alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. <i>Cancer Cytopathology</i> , <b>2020</b> , 128, 107-118	3.9	26
204	Ketogenic diet: a tool for the management of neuroendocrine neoplasms?. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2020</b> , 1-11	11.5	4
203	Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 397	5.7	7
202	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , <b>2020</b> , 271, 527-533	7.8	27

201	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	16
200	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	14
199	Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 610230	5.7	5
198	Aspetti endocrini della neurofibromatosi tipo 1. <i>L Endocrinologo</i> , <b>2019</b> , 20, 261-265	0	
197	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. <i>Cancers</i> , <b>2019</b> , 11,	6.6	16
196	Potenziale metastatico e sopravvivenza dei tumori duodenali e pancreatici nella neoplasia. <i>L Endocrinologo</i> , <b>2019</b> , 20, 111-112	0	
195	Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the "SERENA study", a randomized, double-blind, placebo-controlled trial. <i>Endocrine</i> , <b>2019</b> , 66, 542-550	4	28
194	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1456-1460	3.3	18
193	A rare rarity: Neuroendocrine tumor of the esophagus. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 137, 92-107	7	20
192	Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , <b>2019</b> , 66, 417-424	4	11
191	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2367-2374	5.6	57
190	Amartoma mesenchimale del fegato e Sindrome DICER1. <i>L Endocrinologo</i> , <b>2019</b> , 20, 252-253	0	
189	Carcinoma a cellule di Merkel: gestione clinica e controversie. <i>L Endocrinologo</i> , <b>2019</b> , 20, 127-132	0	
188	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , <b>2019</b> , 19, 1067-1073	3.8	7
187	The role of insulin-like growth factor system in the adrenocortical tumors. <i>Minerva Endocrinologica</i> , <b>2019</b> , 44, 43-57	1.9	12
186	Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. <i>Chemosphere</i> , <b>2019</b> , 218, 885-894	8.4	42
185	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 429-443	4.9	8
184	The management of neuroendocrine tumours: A nutritional viewpoint. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2019</b> , 59, 1046-1057	11.5	26

183	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , <b>2018</b> , 103, 151-163	3.9	14
182	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , <b>2018</b> , 62, 215-233	4	14
181	Open issues on G3 neuroendocrine neoplasms: back to the future. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R375-R384	5.7	7
180	Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R351-R364	5.7	20
179	Clinical presentation and management of patients with primary hyperparathyroidism in Italy. <i>Journal of Endocrinological Investigation</i> , <b>2018</b> , 41, 1339-1348	5.2	22
178	Misurazione e monitoraggio del DNA tumorale circolante nel carcinoma corticosurrenalico. <i>L Endocrinologo</i> , <b>2018</b> , 19, 116-117	0	
177	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , <b>2018</b> , 18, 198-203	3.8	14
176	Tumor Detection in Syndromic NET: Zollinger-Ellison Syndrome <b>2018</b> , 171-178		
175	Significato prognostico del DNA circolante tumorale mutato in RET M918T nei pazienti con carcinoma midollare della tiroide avanzato. <i>L Endocrinologo</i> , <b>2018</b> , 19, 53-54	0	
174	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , <b>2018</b> , 155, 479-489.e7	13.3	36
173	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 607-618	5.7	13
172	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. <i>Endocrine</i> , <b>2018</b> , 62, 46-56	4	9
171	Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R11-R29	5.7	79
170	The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?. <i>Endocrine</i> , <b>2018</b> , 60, 15-27	4	10
169	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 78, 141-154	12.7	28
168	Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study. <i>Neuroendocrinology</i> , <b>2018</b> , 106, 264-273	5.6	6
167	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3200-3206	3.1	23
166	Il citocromo CYP11B1 non svolge alcun ruolo nell'azione e nel metabolismo del mitotane nelle cellule del carcinoma adrenosurrenalico. <i>L Endocrinologo</i> , <b>2018</b> , 19, 225-226	0	



165	Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 67, 1-9	14.4	21
164	Gestione integrata del tumore della prostata: il ruolo dell'endocrinologo. <i>L Endocrinologo</i> , <b>2018</b> , 19, 247-254		
163	Trattamento sequenziale con everolimus e sunitinib in tumori neuroendocrini pancreatici, ben differenziati, metastatici, resistenti alle precedenti terapie. <i>L Endocrinologo</i> , <b>2018</b> , 19, 333-334	0	
162	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	43
161	Nutrition and neuroendocrine tumors: An update of the literature. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2018</b> , 19, 159-167	10.5	23
160	Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R453-R466	5.7	29
159	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , <b>2017</b> , 58, 349-359	4	48
158	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 453-461	6.5	39
157	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 1209-1224	4.9	8
156	Unintentional recurrent laryngeal nerve injuries following thyroidectomy: Is it the surgeon who pays the bill?. <i>International Journal of Surgery</i> , <b>2017</b> , 41 Suppl 1, S55-S59	7.5	31
155	Esplorazione cervicale ecoguidata nell'ipertiroidismo primario. <i>L Endocrinologo</i> , <b>2017</b> , 18, 45-45	0	
154	Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, R223-R237	5.7	26
153	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , <b>2017</b> , 57, 512-517	4	6
152	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , <b>2017</b> , 57, 539-543	4	6
151	Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study. <i>Endocrine Pathology</i> , <b>2017</b> , 28, 187-197	4.2	2
150	Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 661-671	5.6	16
149	Nuove strategie terapeutiche per il trattamento dei NET. <i>L Endocrinologo</i> , <b>2017</b> , 18, 208-213	0	
148	The safety of available treatments options for neuroendocrine tumors. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1149-1161	4.1	17



147	Penetranza e correlazioni genotipo-fenotipo del feocromocitoma e paraganglioma SDHB-correlato. <i>L Endocrinologo</i> , <b>2017</b> , 18, 195-196	0	
146	Tendenza all'aumento dell'incidenza dei tumori neuroendocrini a basso e alto grado. <i>L Endocrinologo</i> , <b>2017</b> , 18, 143-144	0	
145	Fattori genetici ed epigenetici dei tumori neuroendocrini (NET). <i>L Endocrinologo</i> , <b>2017</b> , 18, 248-249	0	
144	Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, 485-493	5.7	21
143	I tumori neuroendocrini ereditari. <i>L Endocrinologo</i> , <b>2017</b> , 18, 123-129	0	
142	Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 1373-1380	5.2	8
141	Animal models of medullary thyroid cancer: state of the art and view to the future. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, R1-R12	5.7	22
140	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. <i>Endocrine</i> , <b>2017</b> , 56, 603-620	4	10
139	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , <b>2017</b> , 56, 633-638	4	25
138	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 9-20	5.2	29
137	Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE). <i>Journal of Endocrinological Investigation</i> , <b>2016</b> , 39, 103-21	5.2	37
136	Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). <i>Endocrine</i> , <b>2016</b> , 52, 495-506	4	32
135	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , <b>2016</b> , 51, 131-9	4	31
134	Quando e come dovrebbero essere sottoposti a screening per tumori carcinoidi timici e bronchiali i pazienti affetti da neoplasie endocrine multiple di tipo 1?. <i>L Endocrinologo</i> , <b>2016</b> , 17, 180-180	0	
133	Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. <i>Annals of Nuclear Medicine</i> , <b>2016</b> , 30, 234-41	2.5	7
132	Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). <i>Endocrine</i> , <b>2016</b> , 52, 488-94	4	30
131	Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. <i>Oncotarget</i> , <b>2016</b> , 7, 5538-47	3.3	24
130	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. <i>Oncotarget</i> , <b>2016</b> , 7, 18865-75	3.3	22

129	Benign thyroid nodules with RAS mutation grow faster. <i>Clinical Endocrinology</i> , <b>2016</b> , 84, 736-40	3.4	18
128	Oncologia endocrina dell'anziano, non solo prostata e mammella: i tumori neuroendocrini in età geriatrica. <i>L Endocrinologo</i> , <b>2016</b> , 17, 309-313	0	
127	Caratteristiche ecografiche del carcinoma midollare della tiroide: esiste una correlazione con i valori pre- e postoperatori di calcitonina?. <i>L Endocrinologo</i> , <b>2016</b> , 17, 275-276	0	
126	Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. <i>Oncologist</i> , <b>2016</b> , 21, 875-86	5.7	9
125	Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, R173-83	5.7	22
124	Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. <i>Clinical and Experimental Dermatology</i> , <b>2016</b> , 41, 38-42	1.8	47
123	Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. <i>Endocrine</i> , <b>2015</b> , 49, 854-8	4	8
122	Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. <i>Endocrine</i> , <b>2015</b> , 50, 824-5	4	2
121	Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 577-583	5.3	33
120	Epidemiology of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , <b>2015</b> , 44, 1-23	3.5	17
119	Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 373-4	5.2	2
118	The evolving field of kinase inhibitors in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 60-73	7	26
117	Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. <i>Endocrine</i> , <b>2015</b> , 49, 274-8	4	7
116	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 193-259	5.2	9
115	Prognostic role of the CDKN1B V109G polymorphism in multiple endocrine neoplasia type 1. <i>Journal of Cellular and Molecular Medicine</i> , <b>2015</b> , 19, 1735-41	5.6	19
114	Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1033-4	6.1	1
113	Pituitary function and morphology in Fabry disease. <i>Endocrine</i> , <b>2015</b> , 50, 483-8	4	4
112	Hepatic arterial embolization in patients with neuroendocrine tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 43	12.8	41

111	GLP-1: benefits beyond pancreas. <i>Journal of Endocrinological Investigation</i> , <b>2014</b> , 37, 1143-53	5.2	23
110	Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Endocrinological Investigation</i> , <b>2014</b> , 37, 875-909	5.2	16
109	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , <b>2014</b> , 19, 966-74	5.7	66
108	Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, R153-63	5.7	180
107	Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. <i>Clinical Endocrinology</i> , <b>2014</b> , 80, 850-5	3.4	29
106	Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy. <i>Journal of Endocrinological Investigation</i> , <b>2014</b> , 37, 1181-6	5.2	16
105	BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay. <i>Endocrine</i> , <b>2014</b> , 45, 249-55	4	18
104	Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. <i>Endocrine</i> , <b>2014</b> , 47, 177-82	4	93
103	Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. <i>Endocrine</i> , <b>2014</b> , 46, 678-81	4	4
102	Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. <i>World Journal of Radiology</i> , <b>2014</b> , 6, 840-5	2.9	4
101	Radioiodide induces apoptosis in human thyroid tissue in culture. <i>Endocrine</i> , <b>2013</b> , 44, 729-34	4	7
100	Spinal deformity index in patients with type 2 diabetes. <i>Endocrine</i> , <b>2013</b> , 43, 651-8	4	16
99	BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 733-8	3.4	29
98	Targeted therapy with kinase inhibitors in aggressive endocrine tumors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1187-203	4	16
97	Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 20-6	3.4	27
96	La gestione multidisciplinare della malattia di Anderson-Fabry: il ruolo dell'endocrinologo. <i>L'Endocrinologo</i> , <b>2013</b> , 14, 213-218	0	
95	Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology. <i>Case Reports in Endocrinology</i> , <b>2013</b> , 2013, 308908	1.2	9
94	Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. <i>Clinical Endocrinology</i> , <b>2013</b> , 78, 760-7	3.4	64

93	Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. <i>Biomarkers</i> , <b>2013</b> , 18, 121-5	2.6	11
92	Hashimoto's Thyroiditis and Entero-Chromaffin-like Cell Hyperplasia: Early Detection and Somatostatin Analogue Treatment. <i>European Journal of Inflammation</i> , <b>2013</b> , 11, 863-870	0.3	3
91	Hereditary Neuroendocrine Tumor Syndromes <b>2013</b> ,		2
90	Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 4439-45	5.6	91
89	Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. <i>Journal of Cellular and Molecular Medicine</i> , <b>2012</b> , 16, 1563-72	5.6	37
88	Limitations of Chromogranin A in clinical practice. <i>Biomarkers</i> , <b>2012</b> , 17, 186-91	2.6	47
87	Insulin resistance and acne: a new risk factor for men?. <i>Endocrine</i> , <b>2012</b> , 42, 555-60	4	34
86	Epidemiology of gastroenteropancreatic neuroendocrine tumours. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2012</b> , 26, 691-703	2.5	153
85	Vitamin D and cancer. <i>Frontiers in Endocrinology</i> , <b>2012</b> , 3, 58	5.7	101
84	Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. <i>Frontiers in Endocrinology</i> , <b>2012</b> , 3, 65	5.7	2
83	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 149-55	5.7	61
82	Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 326-31	5.2	33
81	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 817-23	5.2	48
80	Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding?. <i>Parkinsonism and Related Disorders</i> , <b>2011</b> , 17, 771-3	3.6	6
79	Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. <i>Frontiers in Endocrinology</i> , <b>2011</b> , 2, 20	5.7	26
78	Diabetes and cancer. <i>Frontiers in Endocrinology</i> , <b>2011</b> , 2, 22	5.7	1
77	Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. <i>Endocrine</i> , <b>2011</b> , 39, 283-7	4	47
76	Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound. <i>Radiologia Medica</i> , <b>2011</b> , 116, 595-606	6.5	15

75	Hyperinsulinemic hypoglycemia associated with ectopic Cushing's syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: clinical implications of a rare association. <i>Journal of Endocrinological Investigation</i> , <b>2011</b> , 34, 175-9	5.2	6
74	Possono le alterazioni biochimiche predire la sintomatologia in pazienti affetti da iperparatiroidismo primario?. <i>L Endocrinologo</i> , <b>2011</b> , 12, 260-261	0	
73	CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , <b>2011</b> , 164, 397-404	6.5	25
72	Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients. <i>Hormone and Metabolic Research</i> , <b>2011</b> , 43, 794-800	3.1	22
71	Thyroid function in Fabry disease before and after enzyme replacement therapy. <i>Minerva Endocrinologica</i> , <b>2011</b> , 36, 1-5	1.9	6
70	Thyroid diseases in elderly. <i>Minerva Endocrinologica</i> , <b>2011</b> , 36, 211-31	1.9	18
69	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , <b>2010</b> , 163, 301-8	6.5	95
68	Pituitary carcinomas. <i>Frontiers of Hormone Research</i> , <b>2010</b> , 38, 94-108	3.5	28
67	A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, E32-6	5.6	13
66	Uso degli analoghi della somatostatina nei tumori neuroendocrini: indicazioni e limiti. <i>L Endocrinologo</i> , <b>2010</b> , 11, 40-44	0	
65	Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. <i>Progress in Brain Research</i> , <b>2010</b> , 182, 281-94	2.9	24
64	Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. <i>Clinical Endocrinology</i> , <b>2010</b> , 73, 85-8	3.4	10
63	Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. <i>Thyroid</i> , <b>2009</b> , 19, 219-25	6.2	194
62	Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , <b>2009</b> , 16, 225-31	5.7	24
61	The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 223-30	5.6	250
60	Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. <i>Clinical Endocrinology</i> , <b>2008</b> , 69, 756-62	3.4	29
59	Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 216-23	5.2	31
58	The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 277-86	5.2	41

57	Medical therapy for clinically non-functioning pituitary adenomas. <i>Endocrine-Related Cancer</i> , <b>2008</b> , 15, 905-15	5.7	131
56	US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. <i>Ultrasound in Medicine and Biology</i> , <b>2008</b> , 34, 784-91	3.5	147
55	Cushing's syndrome: aftermath of the cure. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2007</b> , 51, 1381-91		59
54	Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. <i>Cancer</i> , <b>2007</b> , 110, 265-74	6.4	57
53	Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. <i>Modern Pathology</i> , <b>2007</b> , 20, 1172-82	9.8	210
52	Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. <i>Journal of the American Geriatrics Society</i> , <b>2007</b> , 55, 1478-9	5.6	45
51	Functional characterization of human thyroid tissue with immunohistochemistry. <i>Thyroid</i> , <b>2007</b> , 17, 203-11	6.1	43
50	Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. <i>European Journal of Endocrinology</i> , <b>2007</b> , 156 Suppl 1, S57-S63	6.5	34
49	Dopamine receptor expression and function in corticotroph ectopic tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 65-9	5.6	58
48	Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours. <i>Clinical Endocrinology</i> , <b>2007</b> , 66, 1-6	3.4	17
47	Endocrine dysfunction in patients with Fabry disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4319-25	5.6	37
46	MEN1 family with a novel frameshift mutation. <i>Journal of Endocrinological Investigation</i> , <b>2006</b> , 29, 450-6	5.2	7
45	La caratterizzazione biologica dei NET: ruolo diagnostico e prognostico dei marcatori neuroendocrini. <i>L Endocrinologo</i> , <b>2006</b> , 7, 83-92	0	
44	Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. <i>Clinical Endocrinology</i> , <b>2006</b> , 64, 110-3	3.4	43
43	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. <i>Clinical Endocrinology</i> , <b>2006</b> , 65, 536-43	3.4	118
42	The metabolic syndrome and cardiovascular risk in Cushing's syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2005</b> , 34, 327-39, viii	5.5	117
41	Dosimetry of Beta-Emitting Radionuclides at the Tissular Level Using Monte Carlo Methods. <i>Nuclear Science and Engineering</i> , <b>2005</b> , 149, 124-130	1.2	
40	Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. <i>Clinical Endocrinology</i> , <b>2005</b> , 62, 428-33	3.4	20



39	Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 6616-22	5.6	29
38	Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue. <i>Journal of Nuclear Medicine</i> , <b>2004</b> , 45, 232-7	8.9	35
37	Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 2076-80	5.6	69
36	Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1422-31	5.6	82
35	Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 2527-33	5.6	264
34	Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. <i>Clinical Endocrinology</i> , <b>2003</b> , 58, 302-8	3.4	82
33	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , <b>2003</b> , 148, 325-31	6.5	158
32	Differential expression of galectin 3 in solid cell nests and C cells of human thyroid. <i>Journal of Clinical Pathology</i> , <b>2003</b> , 56, 142-3	3.9	16
31	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. <i>Clinical Endocrinology</i> , <b>2002</b> , 56, 153-8	3.4	62
30	Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. <i>Clinical Endocrinology</i> , <b>2002</b> , 57, 813-9	3.4	23
29	Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 142-51	5.2	19
28	Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 163-8	5.2	11
27	Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 932-7	5.2	5
26	Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. <i>Neurological Sciences</i> , <b>2001</b> , 22, 79-80	3.5	14
25	In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 469-77	3.4	22
24	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 97-106	3.4	6
23	Spine abnormalities and damage in patients cured from Cushing's disease. <i>Pituitary</i> , <b>2001</b> , 4, 153-61	4.3	28
22	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. <i>Pituitary</i> , <b>2001</b> , 4, 187-93	4.3	1



21	Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 5256-61	5.6	169
20	Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. <i>European Journal of Endocrinology</i> , <b>2001</b> , 144, 499-507	6.5	92
19	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. <i>European Journal of Endocrinology</i> , <b>2000</b> , 143 Suppl 1, S35-42	6.5	5
18	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , <b>2000</b> , 53, 13-9	3.4	43
17	New medical approaches in pituitary adenomas. <i>Hormone Research in Paediatrics</i> , <b>2000</b> , 53 Suppl 3, 76-87.3	3.3	29
16	Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. <i>European Journal of Endocrinology</i> , <b>2000</b> , 143, 61-9	6.5	10
15	Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1919-24	5.6	138
14	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 2664-72	5.6	291
13	Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 2349-52	5.6	9
12	The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1277-82	5.6	80
11	Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. <i>Journal of Endocrinological Investigation</i> , <b>1999</b> , 22, 860-5	5.2	50
10	Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1919-1924	5.6	130
9	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 2664-2672	5.6	232
8	Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors. <i>Pituitary</i> , <b>1998</b> , 1, 59-67	4.3	12
7	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , <b>1998</b> , 49, 77-84	3.4	12
6	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. <i>Clinical Endocrinology</i> , <b>1998</b> , 48, 655-62	3.4	56
5	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 257-62	5.2	3
4	Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 284-90	5.2	67

3	Impairment of bone status in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 2275-80	5.6	21
2	Impairment of Bone Status in Patients with Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 2275-2280	5.6	18
1	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus		5